- Medicine Name: Pluvicto
- API: Lutetium Lu 177 Vipivotide Tetraxetan
- Dosage Form & Strength: Injection: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial
- Manufactured By: Novartis
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent used for the treatment of adults with advanced cancer known as prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) who have received therapy with androgen receptor pathway inhibition and taxane-based chemotherapy.
Recommended Dosage: The recommended dosage is 7.4 GBq (200 mCi) administered intravenously (IV) every six weeks for up to six doses or until disease progression or unacceptable toxicity. Management of side effects may require temporary dose interruption (extending the dosing interval from every six weeks up to every ten weeks), dose reduction, or permanent discontinuation of therapy with Pluvicto injection. If a treatment delay because of a side effect persists for > 4 weeks, discontinue Pluvicto 1,000 MBq/mL treatment.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.